Research & Development
Diagnostic projects
The levels of circulating GPBP proteins are up-regulated in Goodpasture patients and in animal models undergoing systemic lupus erythematosus and IgA nephropathy. The evidence supports that increased GPBP serum levels is an early event in the pathogenic cascade of glomerular damage towards glomerulosclerosis (type IV collagen expansion). Therefore, GPBP emerges as a new biomarker for immune-complex mediated glomerulonephritis.
FibroStatin SL is developing diagnostic procedures based on immunological detection of GPBP proteins in biological samples. In this regard, our scientists are currently optimizing a proprietary ELISA procedure based on monoclonal antibodies to measure GPBP proteins in biological fluids including human serum. Our prototype is currently being used for large-scale screening of serum collections of patients suffering from immune-complex mediated glomerulonephritis.
Therapeutic projects
Increased levels of circulating GPBP proteins have been associated with its accumulation at the glomerular filtration barrier and glomerulonephritis onset. Additionally, GPBP expression has been found to enhance resistance of cancer cells to chemotherapy. Therefore, GPBP emerges as a new therapeutic target for immune-complex-mediated renal disease and cancer chemoresistance. Basing on GPBP technology, FibroStatin SL is currently developing innovative tools focused on these pathologies.
